-葡萄糖共运输体-1抑制和抑郁:一个门德尔的随机化研究
Gang Fan1,2,3, Hong Zuo2, Xun Shi2
1Clinical Research Center of Xianyang Central Hospital, Shaanxi Province, PR China.
SAGE open medicine
|July 7, 2025
概括
根据孟德尔的随机化,抑制-葡萄糖共载体-1可能会降低欧洲人的抑郁风险. 抑制-葡萄糖共运输体-2与抑郁症风险没有显著关联.
科学领域:
- 药物基因组学 药物基因组学
- 神经科学是一个神经科学.
- 代谢障碍 代谢障碍 代谢障碍
背景情况:
- 观察性研究表明,-葡萄糖携带载体 (SGLT) 抑制剂与抑郁症之间存在联系.
- 需要因果关系证据来证实这种关联.
研究的目的:
- 调查SGLT1/2抑制与抑郁风险之间的因果关系.
- 为了利用孟德尔的随机化来进行强大的遗传分析.
主要方法:
- 用于SGLT1的16个仪器变量和SGLT2抑制的6个仪器变量.
- 采用孟德尔随机化与随机反变异加权方法.
- 分析了来自精神病基因组学联盟和英国生物银行 (n=500,199) 的抑郁症数据.
主要成果:
- 基因预测SGLT1抑制与欧洲人抑郁症风险降低有关 (OR=0.78,p=0.002).
- 在SGLT2抑制和抑郁风险之间没有发现显著的因果关系 (OR=0.98,p=0.919).
结论:
- 在欧洲人口中,SGLT1抑制可能会对抑郁症产生保护作用.
- 需要进一步的研究来阐明潜在的机制.
- 这项研究提供了基因证据,支持SGLT1抑制在治疗抑郁症中的潜在作用.
更多相关视频
08:32Studying the Hypothalamic Insulin Signal to Peripheral Glucose Intolerance with a Continuous Drug Infusion System into the Mouse Brain
Published on: January 4, 2018
10.4K
10:35Extracellular Glucose Depletion as an Indirect Measure of Glucose Uptake in Cells and Tissues Ex Vivo
Published on: April 6, 2022
2.9K
相关概念视频
Glucose Transporters
24.2K
Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
24.2K
Glucose Absorption Into the Small Intestine
32.4K
Complex carbohydrates consumed cannot be absorbed into the small intestine in their original form. First, they must be hydrolyzed to a monosaccharide form such as glucose or galactose. These monosaccharides are then transported across the intestinal membrane and into the blood via transcellular transport. The intestinal epithelial cells allow the movement of these monosaccharides with a defined 'entry' through membrane transporter proteins present on their apical membrane and...
32.4K
Secondary Active Transport
125.0K
One example of how cells use the energy contained in electrochemical gradients is demonstrated by glucose transport into cells. The ion vital to this process is sodium (Na+), which is typically present in higher concentrations extracellularly than in the cytosol. Such a concentration difference is due, in part, to the action of an enzyme “pump” embedded in the cellular membrane that actively expels Na+ from a cell. Importantly, as this pump contributes to the high concentration of...
125.0K
Glucose Homeostasis: Regulation of Blood Glucose
2.6K
Carbohydrates consumed through foods are converted into glucose, a crucial energy source for the body. In the prandial state, high blood glucose levels stimulate the secretion of insulin from the pancreas. Insulin inhibits hepatic glucose production and stimulates glucose uptake and metabolism by muscle and adipose tissue. The excess glucose is converted into glycogen and stored in the liver and muscles.
During fasting, when blood glucose levels are low, the pancreas secretes glucagon. it...
During fasting, when blood glucose levels are low, the pancreas secretes glucagon. it...
2.6K
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
271
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
271
Oral Hypoglycemic Agents: Biguanides and Glitazones
309
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
309
